Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trialsMarcus Maurer, Baldrich Esther Serra, Gordon Sussman et al.|The Lancet|2023Cited by 69
Long-term safety of canakinumab in patients with systemic juvenile idiopathic arthritis: 5-year results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registryDiane E. Brown, Alis Burciu, Amita Bansal et al.|Pediatric Rheumatology|2025Cited by 1